Zelasudil - Redx Pharma
Alternative Names: RXC 007Latest Information Update: 17 Jun 2024
At a glance
- Originator Redx Pharma
- Class Antifibrotics; Antineoplastics; Hepatoprotectants; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Idiopathic pulmonary fibrosis
- Preclinical Fibrosis; Graft-versus-host disease; Interstitial lung diseases; Pancreatic cancer
- Discontinued Diabetic nephropathies; Non-alcoholic steatohepatitis
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 27 Nov 2023 Discontinued - Preclinical for Diabetic nephropathies in United Kingdom (PO) (Redx Pharma pipeline, November 2023)
- 27 Nov 2023 Discontinued - Preclinical for Non-alcoholic steatohepatitis in United Kingdom (PO) (Redx Pharma pipeline, November 2023)